SION · ISSUER CIK 2036042
Sionna Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Sionna Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $21.8M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 1 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$21.8MInsider selling
−$21.8MNet open-market
Sep 21, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 202618:56 | Sep 17, 2026 | SION | Director, 10% Owner · +5 joint | S · Sell | $6.33 | −3,448,811 | 3,448,812 | -50% | −$21.8M | ||
| Sep 18, 202616:59 | Sep 17, 2026 | SION | CFO and CBO | A · Grant | — | +94,537 | 133,069 | +245% | — | ||
| Sep 18, 202616:58 | Sep 17, 2026 | SION | CMO and Head of R&D | A · Grant | — | +100,000 | 128,415 | +352% | — | ||
| Sep 18, 202616:56 | Sep 17, 2026 | SION | CLO and Head of Program Mgmt. | A · Grant | — | +56,265 | 56,265 | New | — | ||
| Sep 18, 202616:52 | Sep 17, 2026 | SION | President & CEO, Director | A · Grant | — | +218,050 | 765,393 | +40% | — |